Not available
Quote | Athersys Inc. (NASDAQ:ATHX)
Last: | $0.1018 |
---|---|
Change Percent: | -37.41% |
Open: | $0.1348 |
Close: | $0.1018 |
High: | $0.1348 |
Low: | $0.0982 |
Volume: | 78,968,068 |
Last Trade Date Time: | 10/17/2023 03:00:00 am |
News | Athersys Inc. (NASDAQ:ATHX)
2023-11-17 06:28:55 ET More on Athersys Athersys crashes after bankruptcy warning Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: Athersys GAAP EPS o...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
Message Board Posts | Athersys Inc. (NASDAQ:ATHX)
Subject | By | Source | When |
---|---|---|---|
Have a look at this | goupupup | investorshub | 05/17/2023 7:08:03 AM |
is it bear time? Or do we go bull? | RagingStocks | investorshub | 05/15/2023 12:43:50 PM |
$ATHX is it bear time? Or do we go bull? | longtrailer | investorshub | 05/15/2023 9:09:36 AM |
MomentumIts now | goupupup | investorshub | 05/13/2023 6:09:30 AM |
$ATHX Price trading up | goupupup | investorshub | 05/13/2023 2:50:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...